Liquidia announced updates and promotions to its operations leadership in advance of the potential approval and launch of Yutrepia – treprostinil – inhalation powder. Michael Kaseta, CFO, has added the role of Chief Operating Officer – COO – to his responsibilities effective on January 15, 2023. In connection with this change, Michael Hunter was also promoted to Senior VP of Manufacturing Operations, where he will manage all day-to-day manufacturing and supply chain operations internally and externally. Simultaneously, former COO Robert Lippe will transition out of the Company over a three-month period.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LQDA:
- Liquidia Corporation Announces Updates to Operations Leadership
- Liquidia Technologies call volume above normal and directionally bullish
- Liquidia files response and counterclaims to United Therapeutics lawsuit
- Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims
- Liquidia added to Conviction Buy, named 2024 Top Pick at Needham